AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
Interest Income Expense
AstraZeneca PLC
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
AstraZeneca PLC
LSE:AZN
|
Interest Income Expense
-$837m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Interest Income Expense
-£1.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-7%
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Interest Income Expense
$12.6m
|
CAGR 3-Years
132%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
Indivior PLC
LSE:INDV
|
Interest Income Expense
$13m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Interest Income Expense
-$67m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Interest Income Expense
-£21m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-14%
|
See Also
What is AstraZeneca PLC's Interest Income Expense?
Interest Income Expense
-837m
USD
Based on the financial report for Dec 31, 2023, AstraZeneca PLC's Interest Income Expense amounts to -837m USD.
What is AstraZeneca PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-2%
Over the last year, the Interest Income Expense growth was -3%. The average annual Interest Income Expense growth rates for AstraZeneca PLC have been -5% over the past three years , -2% over the past five years .